
    
      This is a randomized, placebo-controlled, parallel-group, multicenter, double-blind study of
      Tazarotene Cream, 0.1% in subjects with acne vulgaris. Subjects will be assigned in a 1:1:1
      ratio to test product, reference product, or cream vehicle. Subjects will be admitted into
      the study only after written informed consent has been obtained and all of the inclusion and
      none of the exclusion criteria have been met. Randomized subjects will apply the study
      medication once daily in the evening for 12 weeks (84 days).
    
  